GSK faces fresh allegations of 'inproper conduct' in Iraq

8 April 2014

UK pharma major GlaxoSmithKline (LSE: GSK) is facing allegations of bribery in Iraq, less than a year after the firm started investigations into corruption in China.

The new allegations concern the company hiring government-employed physicians and pharmacists in Iraq as paid sales representatives to promote their products. A GSK spokesman said: “We are investigating allegations of improper conduct in our Iraq business. We have zero tolerance for unethical or illegal behavior.” The company’s statement added that the allegations relate to a small number of individuals in the country, where GSK employs fewer than 60 people. “We are investigating whether there has been any improper conduct and these investigations are ongoing,” it added.

“Corrupt practices”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK